Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-080361
Filing Date
2025-06-02
Accepted
2025-06-02 17:00:31
Documents
4
Period of Report
2025-07-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A sabs_def14a_fy25agm.htm DEF 14A 1209917
2 GRAPHIC img2486859_0.jpg GRAPHIC 127616
3 GRAPHIC img2486859_1.jpg GRAPHIC 455393
4 GRAPHIC img2486859_2.jpg GRAPHIC 171591
  Complete submission text file 0000950170-25-080361.txt   2249984
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39871 | Film No.: 251015915
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)